These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9193736)

  • 1. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
    Lindenmayer JP; Adityanjee ; Vital-Herne M; Bark N; Grochowski S; Moynihan N
    Biol Psychiatry; 1997 Jul; 42(1):6-12. PubMed ID: 9193736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics.
    Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
    Alcohol Clin Exp Res; 1997 Apr; 21(2):220-6. PubMed ID: 9113256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen augments serotonergic activity in postmenopausal women.
    Halbreich U; Rojansky N; Palter S; Tworek H; Hissin P; Wang K
    Biol Psychiatry; 1995 Apr; 37(7):434-41. PubMed ID: 7786956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal responses to the administration of m-chlorophenylpiperazine in patients with seasonal affective disorder and controls.
    Garcia-Borreguero D; Jacobsen FM; Murphy DL; Joseph-Vanderpool JR; Chiara A; Rosenthal NE
    Biol Psychiatry; 1995 May; 37(10):740-9. PubMed ID: 7640329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures.
    Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B
    Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of serum cholesterol levels on meta-chlorophenylpiperazine-evoked neuroendocrine responses in healthy subjects.
    Terao T; Yoshimura R; Ohmori O; Takano T; Takahashi N; Iwata N; Suzuki T; Abe K
    Biol Psychiatry; 1997 May; 41(9):974-8. PubMed ID: 9110103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
    Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses.
    Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
    Biol Psychiatry; 1997 Jun; 41(11):1071-86. PubMed ID: 9146818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval.
    Nappi RE; Sances G; Brundu B; De Taddei S; Sommacal A; Ghiotto N; Polatti F; Nappi G
    Hum Reprod; 2005 Dec; 20(12):3423-8. PubMed ID: 16123089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior.
    Pitchot W; Ansseau M; Gonzalez Moreno A; Lembreghts M; Hansenne M; Wauthy J; Reel C; Jammaer R; Papart P; Sulon J
    Pharmacopsychiatry; 1995 Oct; 28 Suppl 2():91-2. PubMed ID: 8614706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
    Hadigan CM; Walsh BT; Buttinger C; Hollander E
    Biol Psychiatry; 1995 Apr; 37(8):504-11. PubMed ID: 7619973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MCPP challenge test in schizophrenia: hormonal and behavioral responses.
    Iqbal N; Asnis GM; Wetzler S; Kahn RS; Kay SR; van Praag HM
    Biol Psychiatry; 1991 Oct; 30(8):770-8. PubMed ID: 1751620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
    Abi-Saab W; Seibyl JP; D'Souza DC; Karper LP; Gueorgueva R; Abi-Dargham A; Wong ML; Rajhans S; Erdos JP; Heninger GR; Charney DS; Krystal JH
    Psychopharmacology (Berl); 2002 Jun; 162(1):55-62. PubMed ID: 12107618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic responsivity in trichotillomania: neuroendrocrine effects of m-chlorophenylpiperazine.
    Stein DJ; Hollander E; Cohen L; Simeon D; Aronowitz B
    Biol Psychiatry; 1995 Mar; 37(6):414-6. PubMed ID: 7772651
    [No Abstract]   [Full Text] [Related]  

  • 17. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
    Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
    Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.